Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01EY028755 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Eye Institute (NEI) | NIH |
Not provided
Not provided
Not provided
This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Iris Tumors | This group will consist of 50 adults age 18 or older who have been diagnosed with either melanotic or amelanotic iris tumors. Iris tumor diagnosis will be confirmed by biopsy when possible or based upon clinical features (if patient declines biopsy or if not medically indicated) according to standard-of-care guidelines. | ||
| Healthy Controls | This group will consist of 50 adults age 18 and older who have healthy eyes. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Tumor Thickness in Benign vs Malignant Iris Lesions | OCT/OCTA will be used to compare tumor thickness measurements against the conventional Ultrasonic Biomicroscopy (UBM) device. Tumor thickness will be measured in millimeters, and growth of 0.5 mm or greater will be used to differentiate malignant from benign lesions. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Tumor Area in Benign vs Malignant Iris Lesions | Tumor area will be measured by OCT/OCTA in mm2 and compared against conventional UBM measurements. | 6 months |
| Tumor Volume in Benign vs Malignant Iris Lesions |
Not provided
Inclusion Criteria for tumor group:
Inclusion Criteria for healthy control group:
Exclusion Criteria (both groups):
Not provided
Not provided
Not provided
Adults age 18 or older with either healthy eyes or iris tumors
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Denzil Romfh, OD | Contact | 503-494-4351 | romfhd@ohsu.edu | |
| Humberto Martinez, COT | Contact | 503-494-7712 | martinhu@ohsu.edu |
| Name | Affiliation | Role |
|---|---|---|
| David Huang, MD, PhD | Oregon Health and Science University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oregon Health & Science University | Recruiting | Portland | Oregon | 97239 | United States |
Not provided
| ID | Term |
|---|---|
| D015811 | Iris Neoplasms |
| D009369 | Neoplasms |
| D008545 | Melanoma |
| ID | Term |
|---|---|
| D014604 | Uveal Neoplasms |
| D005134 | Eye Neoplasms |
| D009371 | Neoplasms by Site |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Tumor volume will be measured by OCT/OCTA in mm3 and compared against conventional UBM measurements.
| 6 months |
| Effect of Radiation Treatment on Tumor and Surrounding Ocular Structures | Vessel density and tortuosity will both be measured in % occupied by flow pixels on OCT/OCTA. | 6 months after treatment |
| D007499 |
| Iris Diseases |
| D014603 | Uveal Diseases |
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |